ABVX shares surged approximately 30.1% over the last 30 days, climbing from $97.50 on June 26 to $126.86 as of July 27, driven by positive Phase 3 trial data and a landmark $920 million public offering. The stock's rapid recovery followed the release of ABTECT Maintenance Part 2 results on June 29, which alleviated earlier cancer-related safety concerns that had triggered a sharp selloff in early June.

Cava Group shares have fallen approximately 22.9% over the past 30 days, sliding from $83.40 on June 26 to $64.34 as of July 27, 2026. The decline reflects a combination of broad restaurant-sector headwinds, elevated valuation compression, insider selling activity, and cautious sentiment ahead of Q2 2026 earnings expected in mid-August.

Element Solutions shares declined approximately 19.1% over the past 30 days, falling from $45.66 to $36.93, driven primarily by the announced $14.5 billion acquisition by Solstice Advanced Materials. The July 6 merger announcement triggered a sharp sell-off as investors questioned the deal's modest 15% premium and the combined company's diminished pure-play appeal in electronics chemicals.

Applied Optoelectronics (AAOI) shares declined approximately 29.6% over the past 30 days, sliding from $135.69 on June 26 to $95.47 as of July 27, 2026. The selloff was amplified by the stock's elevated beta of 3.69, making it one of the most volatile names in the AI optics and photonics sector.

Viavi Solutions (VIAV) shares have fallen approximately 21% over the last 30 days, dropping from $47.63 on June 26, 2026, to $37.52 as of July 27, amid a broad technology-sector rout and mounting macroeconomic headwinds. The sell-off accelerated following a Weiss Ratings downgrade to D+ (Sell) on July 16, compounded by the expiration of lockup agreements tied to the company's $500 million equity offering in May.

Semtech Corporation (SMTC) shares declined approximately 20% over the past 30 days, falling from around $149.75 at the end of June to $119.54 by late July 2026. A broad semiconductor sector selloff, triggered by TSMC's higher-than-expected capital expenditure guidance and margin warnings, was the primary catalyst behind the pullback.

Forgent Power Solutions shares plunged approximately 35% over the last 30 days, falling from $55.13 on June 26, 2026, to $35.66 as of late July 2026. The primary catalyst was a heavily discounted secondary offering — 43.65 million shares priced at $49.00 — that intensified dilution fears and underscored ongoing private equity monetization pressure.

SIMO plunged -12.44% during Monday's regular session, tumbling from Friday's close of $270.90 to $237.20, as a broad semiconductor and data storage selloff swept through markets. Profit-taking intensified after the stock's massive +194% year-to-date rally, with traders reassessing whether AI-storage optimism had already been fully priced into shares.

ICHR tumbled -13.91% during Monday's regular trading session, falling to $74.51 from Friday's close of $86.55, making it one of the steepest decliners on the Nasdaq. The selloff was driven by a broad semiconductor sector rout, with the group down roughly -3.3%, as names like MaxLinear also fell sharply alongside Ichor.

MXL fell -12.12% during Monday's regular session to $62.91, extending Friday's -21.54% post-earnings collapse and marking a combined two-session loss of roughly -31% from the July 23 close of $91.24. The selloff is a continuation of the "buy-the-rumor, sell-the-news" reaction to Q2 earnings reported July 23 after the close, which beat estimates (EPS $0.35 vs. $0.33 consensus; revenue +55% YoY) and included raised FY2026 optical data center guidance to $210–$230 million.

SLS is trading at $10.69 during Monday's regular session, falling -5.57% from Friday's close of $11.32, reversing a +1% premarket gain. The stock hit an intraday low of $9.60 before a partial bounce, with volume exceeding 7 million shares amid a 20% intraday swing range.

BRUN is trading down -13.75% intraday Monday to ~$18.75, extending Friday's -9.42% selloff, as heavy selling pressure continues during the regular session. The primary catalyst is today's warrant redemption announcement: Boost Run will redeem all outstanding public warrants at just $0.01 each unless exercised by August 20, forcing warrant holders to buy shares at $11.50 or forfeit value entirely.

MPLT plummeted -67.10% to $12.03 during regular trading Monday after reporting mixed Phase 2 ZEPHYR trial results for schizophrenia drug candidate ML-007C-MA. The selloff began in premarket (shares were indicated down -56%) and intensified through the session as investors digested the data.

SPCX fell -5.05% during Monday's regular session, sliding to a fresh all-time low near $109, well below its $135 IPO price and now down roughly -48% from its June peak of $225.64. The selloff marks a "sell the news" reaction after Friday evening's largely successful Starship 13th test flight, which deployed 20 Starlink V3 satellites but failed to generate any after-hours or Monday buying interest.

LVWR surged +93.15% during Monday's regular session to $2.82, extending Friday's +89.61% rally following its Q2 2026 earnings release on July 23. The primary catalyst remains the Q2 report: consolidated revenue rose +55% YoY to $9.1M, electric motorcycle unit sales soared +386%, and the company reaffirmed full-year 2026 guidance.

REPL is trading at $8.16 during Monday's regular session, plunging -15.88% from Friday's close of $9.70, extending a multi-week selloff that has now erased over 25% in the past two weeks. The selloff follows a July 24 S-3/A filing registering up to 25.1 million shares held by Baker Brothers for potential resale, representing roughly 30% of the company's ~84 million shares outstanding.

CAPR plunged -66.24% to approximately $6.65, with the selloff beginning in premarket trading and deepening during the regular session. The FDA released briefing documents ahead of the July 29 advisory committee meeting, with staff reviewers raising substantial concerns about deramiocel's effectiveness for treating Duchenne muscular dystrophy-associated cardiomyopathy.

MPLT plummeted -66.63% to $12.20 as of late morning trading, after closing at $36.56 on Friday. The sell-off began in premarket, where shares had already fallen roughly -56% before the opening bell. The collapse was triggered by mixed Phase 2 ZEPHYR trial results for lead asset ML-007C-MA in schizophrenia. The twice-daily dose met the primary endpoint, but the once-daily dose failed to achieve statistical significance.

LEGN plunged -13.41% during Monday's regular session, falling to $19.24 from Friday's close of $22.22, extending a multi-week selloff that has erased roughly -36% of value since early July. The primary catalyst is the abrupt resignation of CEO Ying Huang, effective July 24, announced before Monday's open. Alan Bash, President of the CARVYKTI Business Unit, steps in as interim CEO while a permanent successor search begins.

Brown & Brown (BRO) is scheduled to release its second-quarter 2026 earnings on Monday, July 27, after the market closes, with a conference call set for Tuesday, July 28, at 8:00 a.m. EDT. Wall Street consensus estimates point to earnings of approximately $1.08 per share on revenue of roughly $1.72 billion , reflecting year-over-year growth of about 4.9% and 34%, respectively.